Cassava Sciences Inc

$2.11
(as of Jun 3, 9:31 AM EST)

Stock Market Guides is not a financial advisor. Our content is strictly educational and should not be considered financial advice.

Ticker Information for Cassava Sciences Inc

Stock Price
$2.11
Ticker Symbol
SAVA
Exchange
NASDAQ

Industry Information for Cassava Sciences Inc

Sector
Healthcare
Industry
Biotechnology

Company Description for Cassava Sciences Inc

Website
https://www.cassavasciences.com
Country
USA
Full Time Employees
30

Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. Cassava Sciences, Inc. was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. The company was incorporated in 1998 and is based in Austin, Texas.

Fundamentals for Cassava Sciences Inc

Market Capitalization
$78,258,800
EBITDA
$-140,314,000
Dividends per Share
P/E Ratio
Forward P/E Ratio
151.52
Earnings per Share
$-1.46
Earnings per Share Estimate Next Year
Profit Margin
Shares Outstanding
48,307,900
Percent Owned by Insiders
12.79%
Percent Owned by Institutions
36.03%
52-Week High
52-Week Low

Technical Indicators for Cassava Sciences Inc

50-Day Moving Average
200-Day Moving Average
RSI
61.91
ATR
0.13

Analyst Ratings for Cassava Sciences Inc

Strong Buy
0
Buy
0
Hold
2
Sell
0
Strong Sell
0

News About Cassava Sciences Inc

Apr 21, 2025, 4:30 PM EST
AUSTIN, Texas, April 21, 2025 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. See more.
Apr 21, 2025, 4:30 PM EST
Cassava Sciences, Inc. See more.
Mar 25, 2025, 11:36 AM EST
Cassava Sciences (NASDAQ:SAVA) said Tuesday it will shut down its Alzheimer's disease program by the end of the second quarter after another Phase 3 trial failure for simufilam, its lead experimental therapy. See more.
Mar 25, 2025, 8:05 AM EST
Simufilam did not show a significant reduction in co-primary endpoints of cognitive or functional decline versus placebo in patients with mild-to-moderate Alzheimer’s diseaseSimufilam continued to demonstrate an overall favorable safety profileCassava’s Alzheimer’s disease development program with simufilam will be completely discontinued by the end of Q2 2025 See more.